Quantcast

Latest Gilead Sciences Stories

2014-07-24 00:21:34

MELBOURNE, Australia, July 24, 2014 /PRNewswire/ -- Announced at the 20th International AIDS Conference in Melbourne, the agreement seeks to increase access to a promising new HIV medicine in 112 developing countries At the AIDS 2014 conference in Melbourne today, the Medicines Patent Pool (MPP) announced a new licensing agreement with Gilead Sciences for tenofovir alafenamide (TAF), a promising new medicine currently...

2014-07-23 12:32:28

CALGARY, July 23, 2014 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that it has appointed Julie Cherrington PhD to act as the President and Chief Executive Officer of Zenith Epigenetics Corp. Julie has an extensive background leading companies focused on the discovery and development of novel cancer therapeutics and is well-versed in the challenges of developing drugs and advancing them into the clinic and through to commercialization. Her...

2014-07-21 23:04:12

Mazzo, Melmed and Meyers Elected to Board La Jolla, Calif. (PRWEB) July 21, 2014 California Healthcare Institute (CHI) announced today the election of three senior executives to serve on its board of directors: James Mazzo, operating partner, Versant Ventures; Shlomo Melmed, M.D., senior vice president, academic affairs and dean of the medical faculty, Cedars-Sinai Medical Center; and Jim Meyers, senior vice president, commercial operations, North America, Gilead Sciences. CHI is a...

2014-07-21 11:19:15

The JAMA Network Journals Among heterosexual African couples in which the male was HIV positive and the female was not, receipt of antiretroviral pre-exposure preventive (PrEP) therapy did not result in significant differences in pregnancy incidence, birth outcomes, and infant growth compared to females who received placebo, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. The authors note that these findings do not provide a definitive conclusion regarding...

2014-06-23 08:29:48

SOUTH SAN FRANCISCO, Calif., June 23, 2014 /PRNewswire/ -- Tobira Therapeutics, a clinical-stage biopharmaceutical company advancing cenicriviroc (CVC) in liver disease and HIV, announced today the appointment of four directors to its Board: Jeffrey H. Cooper, Craig S. Gibbs, Ph.D., Gwen A. Melincoff and Graeme J. Moyle, M.B.B.S., M.D. "I am very pleased to add to our Board of Directors a group of diverse and talented individuals who bring a wealth of experience and unique skill set...

Hepatitis C treatment debate
2014-06-23 05:10:27

redOrbit Staff & Wire Reports - Your Universe Online A new combination therapy could cut treatment time for hepatitis C to just four weeks, but quicker recovery comes with a steep price, as the new medication is said to cost roughly $1,000 per pill. According to Reuters reporter Bill Berkrot, the treatment involves an experimental antiviral drug produced by Bristol-Myers Squibb and Sovaldi, a drug produced by Gilead Sciences Inc. that has reportedly outraged insurance companies and...

2014-06-13 16:23:24

HAYWARD, Calif., June 13, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Dr. Philip Sager, MD, FACC, FAHA, FHRS, to its Board of Directors. Dr. Sager is a Fellow of the American College of Cardiology, a Fellow of the American Heart Association and a Fellow of the Heart Rhythm Society. Dr. Sager has served as a Consulting...

2014-06-12 08:28:17

Agreement is ViiV Healthcare's first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine LONDON, June 12, 2014 /PRNewswire/ -- ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland Ltd (Janssen) for the development and commercialisation of a single-tablet combining dolutegravir (Tivicay®) and Janssen's non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant®([1])). This...

2014-06-12 08:28:09

CORK, Ireland, June 12, 2014 /PRNewswire/ -- Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT(R)) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY(R)) as the sole active ingredients for the maintenance treatment of people living with Human...

2014-06-05 23:03:26

In-demand research report “Chronic Lymphocytic Leukaemia: KOL Insight” worked out by FirstWord is now available at MarketPublishers.com. London, UK (PRWEB) June 05, 2014 Chronic lymphocytic leukaemia (CLL) is the most common type of the leukaemias. Nevertheless, until recently, it has been underserved in terms of effective therapeutic options. However, a revolution in targeted and personalized therapies is tremendously altering the treatment algorithm and also spurs the development of...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related